<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35604654</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>7</Issue><PubDate><Year>2022</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>TDP-43 Accumulation Within Intramuscular Nerve Bundles of Patients With Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>693</StartPage><EndPage>701</EndPage><MedlinePgn>693-701</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e221113</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2022.1113</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Degeneration of neuromuscular junctions and axons is considered an important aspect of the pathomechanism of amyotrophic lateral sclerosis (ALS). However, a mechanism including the role of transactive response DNA-binding protein 43 (TDP-43) in axons has not been pathologically clarified.</AbstractText><AbstractText Label="OBJECTIVE">To identify and characterize the histopathology of peripheral axons in the skeletal muscle of patients with ALS.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This study comprised 2 parts: a postmortem case-control study and a retrospective population-based cohort study with a minimum of 1 year of follow-up. Patients in the cohort study were enrolled from January 1, 2004, to September 30, 2019. The postmortem study included patients with sporadic ALS (SALS) with TDP-43 pathology and control patients with non-ALS disease. The cohort study enrolled patients without a family history of ALS or other neuromuscular disease and those not diagnosed with a muscle disease at biopsy. Patients were excluded if their clinical records were not screened after biopsy, if they were diagnosed with a muscular disease, and if they were harboring known causative genes of ALS. Data were collected between September 2019 and June 2021 and analyzed in June 2021.</AbstractText><AbstractText Label="EXPOSURES">Muscle biopsy or postmortem muscle tissue examination.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Clinical information and muscle pathological characteristics.</AbstractText><AbstractText Label="RESULTS">A total of 10 patients with autopsy-confirmed SALS (mean [SD] age at death, 76.1 [8.5] years; 8 men [80%]) exhibited axonal phosphorylated TDP-43 (pTDP-43)-positive accumulations in intramuscular nerve bundles; the 12 control patients without ALS did not. Among the 114 patients in the cohort study (mean [SD] age, 62.3 [16.1] years; 76 men [67%]), 71 patients (62.3%) exhibited intramuscular nerve bundles; 43 (37.7%) did not. Among those who exhibited pTDP-43-positive intramuscular nerve bundles, 33 patients (22 men [66.7%]; mean [SD] age, 65.2 [15.6] years) were later diagnosed with ALS. The other 38 patients (26 men [68.4%]; mean [SD] age, 59.3 [18.0] years) showed no pTDP-43-positive bundles and did not develop ALS. Among those without evident nerve bundles (28 men [65.1%]; mean [SD] age, 61.3 [15.3] years), 3 were later diagnosed with ALS. Among patients with ALS in the biopsy cohort, 9 with pTDP-43-positive bundles showed only lower motor neuron symptoms at biopsy.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Results of this dual case-control and retrospective cohort study suggest that axonal pTDP-43 accumulations may be characteristic for patients with ALS. As such findings precede clinical fulfillment of the Gold Coast criteria, TDP-43 in nerve bundles may be a novel diagnostic biomarker for ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kurashige</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neuroscience and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morino</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murao</LastName><ForeName>Tomomi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Izumi</LastName><ForeName>Yuishin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugiura</LastName><ForeName>Tomohito</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuraoka</LastName><ForeName>Kazuya</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Diagnostic Pathology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawakami</LastName><ForeName>Hideshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torii</LastName><ForeName>Tsuyoshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maruyama</LastName><ForeName>Hirofumi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Neurol. 2022 Jul 1;79(7):727</RefSource><PMID Version="1">35816181</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Kurashige reported receiving grants from the Taiju Life Social Welfare Foundation, Takeda Science Foundation, and the Tsuchiya Memorial Medical Foundation during the conduct of the study. Dr Izumi reported receiving grants from the Japan Agency for Medical Research and Development, the Ministry of Health, Labor and Welfare, Takeda Pharmaceutical Company Limited, and Sumitomo Dainippon Pharma Company Limited outside the submitted work. Dr Maruyama reported receiving grants from Grants-in-Aid for Scientific Research, Eisai, Takeda Pharmaceutical, Otsuka Pharmaceutical, Nihon Pharmaceutical, Shionogi, Teijin Pharma, Fuji Film, Sumitomo Dainippon Pharma, Nihon Medi-Physics, Daiichi Sankyo, Kyowa Kirin, Sanofi, Novartis, Tsumura, Japan Blood Products Organization, Pfizer, Astellas Pharma, and grants from Mitsubishi Tanabe Pharma outside the submitted work; and speaker fees from Eisai, Pfizer, Takeda Pharmaceutical, Otsuka Pharmaceutical, Nihon Pharmaceutical, Teijin Pharma, Sumitomo Dainippon Pharma, Daiichi Sankyo, Kyowa Kirin, Novartis, Mitsubishi Tanabe Pharma, Ono Pharmaceutical, Biogen, Bristol Myers Squibb, AbbVie GK, Chugai Pharmaceutical, CSL Behring, UCB Japan, Alexion Pharma, Amgen, Boehringer Ingelheim, Bayer, MSD, Astellas Pharma, and Japan Blood Products Organization. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>23</Day><Hour>11</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35604654</ArticleId><ArticleId IdType="pmc">PMC9127711</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2022.1113</ArticleId><ArticleId IdType="pii">2792745</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ince PG, Highley JR, Wharton SB. Motor neuron disorders. In: Love S, Perry A, Ironside J, Budka H, eds. Greenfield&#x2019;s Neuropathology. 9th ed. CRC Press, 2015.</Citation></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et al. . Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942-955. doi:10.1016/S0140-6736(10)61156-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubbay SS, Kahana E, Zilber N, Cooper G, Pintov S, Leibowitz Y. Amyotrophic lateral sclerosis: a study of its presentation and prognosis. J Neurol. 1985;232(5):295-300. doi:10.1007/BF00313868</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00313868</ArticleId><ArticleId IdType="pubmed">4056836</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, et al. . Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130-133. doi:10.1126/science.1134108</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Mackenzie IRA. Review: neuropathology of nontau frontotemporal lobar degeneration. Neuropathol Appl Neurobiol. 2019;45(1):19-40. doi:10.1111/nan.12526</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12526</ArticleId><ArticleId IdType="pubmed">30357887</ArticleId></ArticleIdList></Reference><Reference><Citation>Onozato T, Nakahara A, Suzuki-Kouyama E, et al. . Axonal TDP-43 aggregates in sporadic amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol. 2016;42(6):561-572. doi:10.1111/nan.12310</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12310</ArticleId><ArticleId IdType="pubmed">26819002</ArticleId></ArticleIdList></Reference><Reference><Citation>England JD, Asbury AK. Peripheral neuropathy. Lancet. 2004;363(9427):2151-2161. doi:10.1016/S0140-6736(04)16508-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(04)16508-2</ArticleId><ArticleId IdType="pubmed">15220040</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer LR, Culver DG, Tennant P, et al. . Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol. 2004;185(2):232-240. doi:10.1016/j.expneurol.2003.10.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2003.10.004</ArticleId><ArticleId IdType="pubmed">14736504</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer LR, Glass JD. Axonal degeneration in motor neuron disease. Neurodegener Dis. 2007;4(6):431-442. doi:10.1159/000107704</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000107704</ArticleId><ArticleId IdType="pubmed">17934327</ArticleId></ArticleIdList></Reference><Reference><Citation>Iguchi Y, Katsuno M, Niwa J, et al. . Loss of TDP-43 causes age-dependent progressive motor neuron degeneration. Brain. 2013;136(Pt 5):1371-1382. doi:10.1093/brain/awt029</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt029</ArticleId><ArticleId IdType="pubmed">23449777</ArticleId></ArticleIdList></Reference><Reference><Citation>Isak B, Pugdahl K, Karlsson P, et al. . Quantitative sensory testing and structural assessment of sensory nerve fibres in amyotrophic lateral sclerosis. J Neurol Sci. 2017;373:329-334. doi:10.1016/j.jns.2017.01.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2017.01.005</ArticleId><ArticleId IdType="pubmed">28131214</ArticleId></ArticleIdList></Reference><Reference><Citation>Alami NH, Smith RB, Carrasco MA, et al. . Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron. 2014;81(3):536-543. doi:10.1016/j.neuron.2013.12.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.12.018</ArticleId><ArticleId IdType="pmc">PMC3939050</ArticleId><ArticleId IdType="pubmed">24507191</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagano S, Jinno J, Abdelhamid RF, et al. . TDP-43 transports ribosomal protein mRNA to regulate axonal local translation in neuronal axons. Acta Neuropathol. 2020;140(5):695-713. doi:10.1007/s00401-020-02205-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02205-y</ArticleId><ArticleId IdType="pubmed">32803350</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotem N, Magen I, Ionescu A, et al. . ALS along the axons&#x2014;expression of coding and noncoding RNA differs in axons of ALS models. Sci Rep. 2017;7:44500. doi:10.1038/srep44500</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep44500</ArticleId><ArticleId IdType="pmc">PMC5353576</ArticleId><ArticleId IdType="pubmed">28300211</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman T, Ionescu A, Ibraheem A, et al. . Axonal TDP-43 condensates drive neuromuscular junction disruption through inhibition of local synthesis of nuclear encoded mitochondrial proteins. Nat Commun. 2021;12(1):6914. doi:10.1038/s41467-021-27221-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27221-8</ArticleId><ArticleId IdType="pmc">PMC8617040</ArticleId><ArticleId IdType="pubmed">34824257</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Al-Chalabi A, Baker MR, et al. . A proposal for new diagnostic criteria for ALS. Clin Neurophysiol. 2020;131(8):1975-1978. doi:10.1016/j.clinph.2020.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2020.04.005</ArticleId><ArticleId IdType="pubmed">32387049</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwong LK, Neumann M, Sampathu DM, Lee VM, Trojanowski JQ. TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease. Acta Neuropathol. 2007;114(1):63-70. doi:10.1007/s00401-007-0226-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0226-5</ArticleId><ArticleId IdType="pubmed">17492294</ArticleId></ArticleIdList></Reference><Reference><Citation>Cykowski MD, Powell SZ, Appel JW, Arumanayagam AS, Rivera AL, Appel SH. Phosphorylated TDP-43 (pTDP-43) aggregates in the axial skeletal muscle of patients with sporadic and familial amyotrophic lateral sclerosis. Acta Neuropathol Commun. 2018;6(1):28. doi:10.1186/s40478-018-0528-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0528-y</ArticleId><ArticleId IdType="pmc">PMC5899326</ArticleId><ArticleId IdType="pubmed">29653597</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori F, Tada M, Kon T, et al. . Phosphorylated TDP-43 aggregates in skeletal and cardiac muscle are a marker of myogenic degeneration in amyotrophic lateral sclerosis and various conditions. Acta Neuropathol Commun. 2019;7(1):165. doi:10.1186/s40478-019-0824-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0824-1</ArticleId><ArticleId IdType="pmc">PMC6816170</ArticleId><ArticleId IdType="pubmed">31661037</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>